Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1650237 | 0.98 | CYP3A4 (0.40) | TSHRCYP3A4ALDH1A1HSD17B10HPGD | |
| SCHEMBL20698677 | 0.81 | CYP3A4 (0.32) | TSHRCYP3A4 | |
| SCHEMBL19374125 | 0.80 | NPSR1 (0.36) | TSHRCYP3A4CYP1B1TRPA1 | |
| SCHEMBL242542 | 0.75 | — | — | |
| SCHEMBL29517242 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL2251205 | 0.73 | TRPA1 (0.43) | TSHRPARP1PLAUTRPA1 | |
| Hydrochloric Acid SCHEMBL31416539 | 0.73 | TRPA1 (0.43) | TSHRPARP1PLAUTRPA1 | |
| SCHEMBL27462406 | 0.73 | — | — | |
| SCHEMBL1502427 | 0.72 | ALDH1A1 (0.34) | TSHRALDH1A1HSD17B10CYP1A2CYP2C19 | |
| SCHEMBL9017214 | 0.72 | TDP1 (0.42) | TSHRALDH1A1CYP1A2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0062844-B1 | SUBSTITUTED BENZO(DE)ISOQUINOLINES, PROCESSES FOR THEIR PREPARATION, AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Beiersdorf Aktiengesellschaft (DE) | 1984-11-28 | — | — | EP | claimed |
| JP-8166690-A | — | — | None | — | — | JP | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179567-A2 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2014-11-06 | — | — | WO | disclosed |
| EP-2776017-A1 | GOLD COMPOUNDS HAVING ALKYNYL LIGANDS AND THERAPEUTIC USE THEREOF | Technische Universität Braunschweig Carolo-Wilhelmina (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-4874863-A | Bisnaphthalimides | KNOLL AG (DE) | 1989-10-17 | — | — | US | disclosed |
| EP-0281902-A1 | Bis-naphthalimides, their preparation and use | KNOLL AG (DE) | 1988-09-14 | — | — | EP | disclosed |
| EP-0268093-A1 | 5-Nitrobenzo[de]isoquinoline-1,3 diones, their preparation and use | KNOLL AG (DE) | 1988-05-25 | — | — | EP | disclosed |
| EP-0062844-B1 | SUBSTITUTED BENZO(DE)ISOQUINOLINES, PROCESSES FOR THEIR PREPARATION, AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Beiersdorf Aktiengesellschaft (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0062844-B1 | SUBSTITUTED BENZO(DE)ISOQUINOLINES, PROCESSES FOR THEIR PREPARATION, AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Beiersdorf Aktiengesellschaft (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0062844-A1 | Substituted benzo(de)isoquinolines, processes for their preparation, and their application as pharmaceutical preparations | Beiersdorf Aktiengesellschaft (DE) | 1982-10-20 | — | — | EP | disclosed |
| EP-0062844-A1 | Substituted benzo(de)isoquinolines, processes for their preparation, and their application as pharmaceutical preparations | Beiersdorf Aktiengesellschaft (DE) | 1982-10-20 | — | — | EP | disclosed |
| EP-0062844-A1 | Substituted benzo(de)isoquinolines, processes for their preparation, and their application as pharmaceutical preparations | Beiersdorf Aktiengesellschaft (DE) | 1982-10-20 | — | — | EP | disclosed |
| US-4254109-A | INHIBIT LENS ALDOSE REDUCTASE | AYERST, MCKENNA & HARRISON INC. (CA) | 1981-03-03 | — | — | US | disclosed |
| US-4254108-A | ALDOSE REDUCTASE INHIBITORS | AYERST, MCKENNA & HARRISON INC. (CA) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | TSHR 4522/4885CYP3A4 493/4885ALDH1A1 1520/4885 |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | TSHR 3540/4885CYP3A4 3368/4885ALDH1A1 921/4885 |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | TSHR 3540/4885CYP3A4 3368/4885ALDH1A1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.